This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viemed Healthcare, Inc. (VMD) Lags Q1 Earnings Estimates
by Zacks Equity Research
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -33.33% and 1.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
What's in Store for West Pharmaceutical's (WST) Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.
Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay
by Zacks Equity Research
Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.
Haemonetics (HAE) Up 4.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given strong recovery across businesses and strength in plasma franchise.
Haemonetics (HAE) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Haemonetics (HAE) exited the fiscal third quarter with better-than-expected earnings and robust growth across Hospital business, driving the top line.
Haemonetics (HAE) Q3 Earnings Beat Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 12% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Haemonetics (HAE) Ahead of Earnings?
by Zacks Equity Research
Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Haemonetics (HAE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
by Zacks Equity Research
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
Haemonetics (HAE) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of -4.76% and -2.44%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.